Patrik De Haes, CEO, Oxurion 00:00:00
CEO Patrik De Haes, MD, said Oxurion is a public company in Europe based on treating diabetic eye disease with three proprietary molecules. He expects the second half of this year will be quite intense, because they will have data from all 4 of their current clinical trials.